Ahmet Hakan GEDİK, Erkan ÇAKIR, Aysel Vehapoğlu TÜRKMEN, Ömer Faruk ÖZER, Sare Betül KAYGUSUZ

Total oxidant and antioxidant status and paraoxonase 1 levels ofchildren with noncystic fibrosis bronchiectasis

Background/aim: To evaluate total oxidant status TOS , total antioxidant capacity TAC , and paraoxonase 1 PON1 levels in children with noncystic fibrosis CF bronchiectasis BE , and to compare these levels with those of healthy controls. The study parameters were also evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions. Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1 levels were determined. Lung function tests were performed by spirometry. Results: Serum TOS was higher in the patients [median 9.54 IQR 25-75 = 7.05-13.30 µmol H2O2 Eq/L] than in the healthy subjects [6.64 5.45-9.53 µmol H2O2 Eq/L] P

Keywords:

Bronchiectasis noncystic fibrosis bronchiectasis, paraoxonase, total oxidant status, total antioxidant capacity, children,

PDF

___

1. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 2010; 65: 1-58.
2. Bergin DA, Hurley K, Mehta A, Cox S, Ryan D, O’Neill SJ, Reeves EP, McElvaney NG. Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 2013; 6: 1-11.
3. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207.
4. Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, Amargianitakis V, Gousiou A, Menikou S, Siafakas NM. Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest 2012; 141: 1243-1250.
5. Heunks LMA, Dekhuijzen PN. Respiratory muscle function and free radicals: from cell to COPD. Thorax 2000; 55: 704-716.
6. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4: 523-532.
7. Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013; 17: 829-837.
8. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003; 111: 72-78.
9. Soler N, García-Heredia A, Marsillach J, Mackness B, Mackness M, Joven J, Romero P, Camps J. Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease. Invest Ophthalmol Vis Sci 2013; 54: 5852-5858.
10. Back EI, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke M, Biesalski HK. Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr 2004; 80: 374-384.
11. Lezo A, Biasi F, Massarenti P, Calabrese R, Poli G, Santini B, Bignamini E. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? J Cyst Fibros 2013; 12: 35-41.
12. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406.
13. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol, Reg Integr Comp Physiol 2004; 286: 431-444.
14. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.
15. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119.
16. Bonovita J, Naidich DP. Imaging of bronchiectasis. Clin Chest Med 2012; 32: 233-248.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A. Standardization of spirometry. Eur Respir J 2005; 26: 319-338.
18. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
19. Henricks PA, Nijkamp FP. Reactive oxygen species as mediators in asthma. Pulm Pharmacol Ther 2001; 14: 409-420.
20. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-623.
21. Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol 2008; 8: 49-56.
22. Selek S, Aslan M, Horoz M, Celik H, Cosar N, Gunak F, Kocyigit A. Peripheral DNA damage in active pulmonary tuberculosis. Environ Toxicol 2012; 27: 380-384.
23. Cristóvão C, Cristóvão L, Nogueira F, Bicho M. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. Rev Port Pneumol 2013; 19: 70-75.
24. Rai RR, Phadke MS. Plasma oxidant-antioxidant status in different respiratory disorders. Indian J Clin Biochem 2006; 21: 161-164.
25. Olveira G, Olveira C, Dorado A, García-Fuentes E, Rubio E, Tinahones F, Soriguer F, Murri M. Cellular and plasma oxidative stress biomarkers are raised in adults with bronchiectasis. Clin Nutr 2013; 32: 112-117.
26. Cakmak A, Zeyrek D, Atas A, Celik H, Aksoy N, Erel O. Serum prolidase activity and oxidative status in patients with bronchial asthma. J Clin Lab Anal 2009; 23: 132-138.
27. Koc S, Aksoy N, Bilinc H, Duygu F, Uysal IÖ, Ekinci A. Paraoxonase and arylesterase activity and total oxidative/antioxidative status in patients with chronic adenotonsillitis. Int J Pediatr Otorhinolaryngol 2011; 75: 1364-1367.
28. Rumora L, Rajković MG, Kopčinović LM, Pancirov D, Cepelak I, Grubišić TZ. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease. COPD 2014; 11: 539-545.
29. Acay A, Erdenen F, Altunoglu E, Erman H, Muderrisoglu C, Korkmaz GG, Gelisgen R, Tabak O, Uzun H. Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease. Clin Lab 2013; 59: 1331-1337.